NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
Stans, Switzerland (ots) - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the pricing of its initial public offering of 4,819,277 units at a price of ...
mehr